---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116252"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:32:11.256932+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharma Q3 2022: Record revenue $83.8M (+61% YoY); GAAP loss $(9.0M); adj. EPS $0.64; Cortrophin $12.6M

## Summary
- Record net revenues of $83.8M, up 61% YoY from $52.1M.
- GAAP net loss $(9.0M) and diluted loss per share $(0.55), compared to loss $(4.4M) and $(0.37) in Q3 2021.
- Adjusted non-GAAP EBITDA $19.6M (nearly double Q2 2022) and adjusted diluted EPS $0.64, down from $1.01 in Q3 2021.
- Cortrophin net sales $12.6M; cumulative patient cases 765+; reiterated full-year Cortrophin revenue guidance $40-45M; full-company guidance also reaffirmed.

## SEC filing metadata
- accession: 0001104659-22-116252
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/0001104659-22-116252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/tm2230118d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116252
- JSON: https://secwatch.observer/filing/0001104659-22-116252.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116252.txt

## Key facts
- Earnings Releases
  ANI PHARMACEUTICALS INC reported three and nine months ended September 30, 2022 results: revenue $83.8 million, net income $(9.0) million, EPS $(0.55). Guidance reaffirmed.
  - Period: three and nine months ended September 30, 2022
  - Revenue: $83.8 million
  - Net income: $(9.0) million
  - EPS: $(0.55)
  - Guidance: reaffirmed
  - Result: reported results
  source text: ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues Third Quarter 2022 Results: -- Net revenues of $83.8 million, net loss available to common shareholders of $(9.0) million and diluted GAAP loss per share of $(0.55)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1023024/000110465922116252/0001104659-22-116252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.